Table 4 |
||||
|
Comparison of HLA class II phenotypes in serological subsetsa |
||||
| HLA phenotype/serology |
n (%) |
p |
pcorr |
OR (95% CI) |
|
|
||||
| DRB1*03 |
||||
| Synthetase |
44 (84.6) |
1 × 10-15 |
1 × 10-14 |
14.1 (6.3–35.2) |
| PM-Scl |
11 (100) |
3 × 10-6 |
4 × 10-5 |
30.6 (4.4–1309.1) |
| DRB1*07 |
||||
| Mi-2 |
14 (77.8) |
4 × 10-6 |
5 × 10-5 |
11.1 (3.4–46.8) |
| DQA1*02 |
||||
| Mi-2 |
14 (77.8) |
9 × 10-6 |
5 × 10-5 |
11.6 (3.3–50.6) |
| DQA1*05 |
||||
| Synthetase |
42 (85.7) |
7 × 10-9 |
4 × 10-8 |
9.5 (3.8–26.5) |
| PM-Scl |
11 (100) |
0.0002 |
0.001 |
18.9 (2.6–814.9) |
| DQB1*02 |
||||
| Synthetase |
42 (85.7) |
6.6 × 10-9 |
4 × 10-8 |
9.5 (3.8–26.5) |
| Mi-2 |
15 (83.3) |
7 × 10-4 |
0.004 |
7.5 (2.0–41.9) |
| PM-Scl |
11 (100) |
0.0003 |
0.001 |
18.0 (2.5–777.4) |
|
|
||||
|
aResults are versus controls. CI, confidence interval; OR, odds ratio; p, probability; pcorr, corrected probability. |
||||
|
Chinoy et al. Arthritis Research & Therapy 2006 8:R13 doi:10.1186/ar1862 |
||||
